Stay updated on Expanded Access Risdiplam in SMA Clinical Trial
Sign up to get notified when there's something new on the Expanded Access Risdiplam in SMA Clinical Trial page.

Latest updates to the Expanded Access Risdiplam in SMA Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays the ClinicalTrials.gov record for an expanded-access risdiplam program for people with Type 1 or Type 2 spinal muscular atrophy, including participation criteria, treatment details, locations, and record history.SummaryDifference43%

- Check8 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check15 days agoChange DetectedA sitewide NIH notice about terminology changes under Executive Order 14434 was added. The site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check29 days agoChange DetectedThe error page’s displayed site revision was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the expected study record content. The change removes the previously visible study details and related terms, leaving only site chrome and the footer.SummaryDifference15%

- Check72 days agoChange DetectedThe Study Record Dates now display Revision: v3.6.6, replacing the previous v3.6.5, indicating a minor page metadata update without substantive changes to the study details.SummaryDifference0.1%

Stay in the know with updates to Expanded Access Risdiplam in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access Risdiplam in SMA Clinical Trial page.